<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="40331">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02093923</url>
  </required_header>
  <id_info>
    <org_study_id>DX-2930-02</org_study_id>
    <nct_id>NCT02093923</nct_id>
  </id_info>
  <brief_title>Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects</brief_title>
  <official_title>A Phase 1b, Double-Blind, Multiple Ascending Dose Study to Assess Safety, Tolerability and Pharmacokinetics of DX-2930 in Hereditary Angioedema Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dyax Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dyax Corp.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety, tolerability, and PK profile of
      multiple subcutaneous administrations of DX-2930 across a range of doses in HAE subjects.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2014</start_date>
  <completion_date type="Anticipated">March 2015</completion_date>
  <primary_completion_date type="Anticipated">March 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>proportion of patients with non-serious and serious adverse events</measure>
    <time_frame>through 4 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>DX-2930 plasma level</measure>
    <time_frame>through 4 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Hereditary Angioedema</condition>
  <arm_group>
    <arm_group_label>DX-2930, Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DX-2930 administered twice, two weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DX-2930, Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DX-2930 administered twice, two weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>DX-2930, Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DX-2930 administered twice, two weeks apart</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DX-2930</intervention_name>
    <description>DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody</description>
    <arm_group_label>DX-2930, Cohort 1</arm_group_label>
    <arm_group_label>DX-2930, Cohort 2</arm_group_label>
    <arm_group_label>DX-2930, Cohort 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>DX-2930, Cohort 1</arm_group_label>
    <arm_group_label>DX-2930, Cohort 2</arm_group_label>
    <arm_group_label>DX-2930, Cohort 3</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 18 years of age at the time of screening.

          -  Documented diagnosis of HAE (Type I or II)

          -  Experiencing â‰¥2 HAE attacks per year, with at least 1 attack in the past 6 months
             reported by the subject.

          -  Willing and able to read, understand, and sign an informed consent form.

          -  Females of childbearing potential must agree to be abstinent or else use acceptable
             forms of contraception throughout study

          -  Males with female partners of childbearing potential must agree to be abstinent or
             use a medically acceptable form of contraception throughout study.

        Exclusion Criteria:

          -  Exposure to an investigational drug or device within 90 days prior to study.

          -  History of exposure within the past 5 years to a monoclonal antibody or recombinant
             protein bearing an Fc domain.

          -  Concomitant diagnosis of another form of chronic angioedema

          -  Use of long-term prophylaxis for HAE within 90 days prior to study.

          -  Use of C1-INH that exceeds a total of 30 days within the past 90 days prior to study;
             any use of C1-INH within 7 days prior to study.

          -  Exposure to angiotensin-converting enzyme (ACE) inhibitors or any estrogen-containing
             medications with systemic absorption within 90 days prior to study.

          -  Exposure to androgens within 90 days prior to study.

          -  Presence of an indwelling catheter.

          -  Diagnosis of HIV.

          -  Active liver disease or liver function test abnormalities

          -  History of substance abuse or dependence.

          -  Pregnancy or breastfeeding.

          -  Any condition that, in the opinion of the Investigator, may compromise their safety
             or compliance, preclude successful conduct of the study, or interfere with
             interpretation of the results
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ryan Iarrobino</last_name>
    <phone>617-250-5574</phone>
    <email>riarrobino@dyax.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Joshua S. Jacobs, MD</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Joshua S Jacobs, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aleena Banerji, MD</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Aleena Banerji, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Jonathan A. Bernstein, MD</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jonathan A Bernstein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James W. Baker, MD</name>
      <address>
        <city>Lake Oswego</city>
        <state>Oregon</state>
        <zip>97035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>James W Baker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>William R. Lumry, MD</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>William R Lumry, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 28, 2014</lastchanged_date>
  <firstreceived_date>March 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HAE</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Angioedema</mesh_term>
    <mesh_term>Angioedemas, Hereditary</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
